NMPA STC-1010 coverage for business development, investment, and market access teams
Brenus Pharma has announced the FDA's acceptance of its IND application for STC-1010 in MSS metastatic colorectal cancer. This development could significantly impact the competitive landscape and investment opportunities.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
